Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -23.59 is 100% above its 5-year average of -249058.36, near the high end of its 5-year range (-512208.00–-23.59).
90.61% above its 12-month average of -251.09.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.38.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-23.59
EARNINGS PER SHARE (EPS) AVG TTM
-251.09
EARNINGS PER SHARE (EPS) AVG 3Y
-121778.80
EARNINGS PER SHARE (EPS) AVG 5Y
-249058.36
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+90.61%
CURRENT VS 3Y AVG
+99.98%
CURRENT VS 5Y AVG
+99.99%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CNS Pharmaceuticals, Inc.
Market Cap
$7.42M
Earnings Per Share (EPS)
-23.59
TTM Avg
-251.09
3Y Avg
-121778.80
5Y Avg
-249058.36
Market Cap
$7.33M
Earnings Per Share (EPS)
-10.10
TTM Avg
-11.80
3Y Avg
-53.95
5Y Avg
-54.65
Market Cap
$7.31M
Earnings Per Share (EPS)
-3.48
TTM Avg
-5.74
3Y Avg
-24.14
5Y Avg
-2936.24
Market Cap
$7.62M
Earnings Per Share (EPS)
-68.91
TTM Avg
-299.00
3Y Avg
-268.50
5Y Avg
-367.67
Market Cap
$7.23M
Earnings Per Share (EPS)
-7.38
TTM Avg
-1.62
3Y Avg
-0.82
5Y Avg
-0.82
Market Cap
$7.09M
Earnings Per Share (EPS)
-81.82
TTM Avg
-336.50
3Y Avg
-753.63
5Y Avg
-537.05
Market Cap
$7.08M
Earnings Per Share (EPS)
-8.91
TTM Avg
-9.90
3Y Avg
-14.45
5Y Avg
-12.10
Market Cap
$6.98M
Earnings Per Share (EPS)
-1.16
TTM Avg
-3.29
3Y Avg
-3.69
5Y Avg
-2.95
Market Cap
$7.95M
Earnings Per Share (EPS)
-104.00
TTM Avg
-164.88
3Y Avg
-121.81
5Y Avg
-116.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.42M | -23.59 | -251.09 | -121778.80 | -249058.36 |
| Longeveron Inc. (LGVN)vs › | $7.33M | -10.10 | -11.80 | -53.95 | -54.65 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -3.48 | -5.74 | -24.14 | -2936.24 |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.62M | -68.91 | -299.00 | -268.50 | -367.67 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | -7.38 | -1.62 | -0.82 | -0.82 |
| KALA BIO, Inc. (KALA)vs › | $7.09M | -81.82 | -336.50 | -753.63 | -537.05 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | -8.91 | -9.90 | -14.45 | -12.10 |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -1.16 | -3.29 | -3.69 | -2.95 |
| GT Biopharma, Inc. (GTBP)vs › | $7.95M | -104.00 | -164.88 | -121.81 | -116.67 |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | -6.39 | -9.59 | -7.41 | -7.93 |
Trailing EPS (TTM)
$-23.59
Forward EPS (Est.)
$-1.65
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -35.75 |
| 2024-12-31 | -466.44 |
| 2023-12-31 | -150114.00 |
| 2022-12-31 | -336499.00 |
| 2021-12-31 | -495027.00 |
| 2020-12-31 | -512208.00 |
| 2019-12-31 | -212121.00 |
| 2018-12-31 | -404415.00 |
| 2017-12-31 | -11997.00 |
